CCND1抗体;CCND1 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using CCND1 mouse mAb against LNCAP (1), A431 (2), and NIH/3T3 (3) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using CCND1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues using CCND1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human brain tissues using CCND1 mouse mAb with DAB staining.    

  
  

The CCND1 antibody is a crucial tool in molecular and cancer research, targeting cyclin D1. a key regulator of the cell cycle. Cyclin D1 (encoded by the *CCND1* gene) belongs to the cyclin protein family and plays a pivotal role in driving the G1-to-S phase transition by forming complexes with cyclin-dependent kinases (CDKs), primarily CDK4/6. These complexes phosphorylate retinoblastoma (Rb) protein, releasing transcription factors that promote cell cycle progression. Dysregulation of CCND1. often due to gene amplification, chromosomal translocation, or transcriptional upregulation, is implicated in various cancers, including breast cancer, mantle cell lymphoma, and multiple myeloma, making it a biomarker of oncogenic activity.

CCND1 antibodies are widely used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein expression levels in tissues or cell lines. Researchers utilize these antibodies to study cell cycle abnormalities, tumorigenesis mechanisms, and therapeutic responses, particularly in cancers with CCND1 overexpression. Additionally, CCND1 antibodies aid in evaluating the efficacy of CDK4/6 inhibitors, a class of targeted cancer therapies. Their specificity varies depending on epitope targets (e.g., N-terminal or C-terminal regions), and validation for intended applications is critical. Understanding CCND1's role in cellular proliferation and its association with poor prognosis underscores the antibody's relevance in both basic research and clinical diagnostics.